KINETICS OF MOLECULAR RECOGNITION MEDIATED NANOPARTICLE SELF-ASSEMBLY

• US 20100261212A1
• Filed: 01/11/2010
• Published: 10/14/2010
• Est. Priority Date: 01/09/2009
• Status: Abandoned Application

• Current Assignee: Chinmay Prakash Soman, Todd Donald Giorgio
• Original Assignee: Chinmay Prakash Soman, Todd Donald Giorgio
• Inventors: Giorgio, Todd Donald, Soman, Chinmay Prakash
• Application Number:
  US12/685,597
• Publication Number:
  US 20100261212A1
• Time in Patent Office: Days
• US Class Current: 435/21
• CPC Class Codes: B82Y 15/00 Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
• CPC Class Codes: G01N 33/588 with semiconductor nanocrystal label, e.g. quantum dots

Abstract

A method of multiple protein biomarker detection, comprising providing at quantum dot-antibody conjugates that have an affinity for at least two different protein biomarkers; contacting the conjugates with a sample from a subject; allowing the proteins to bridge the antibodies, forming protein biomarker/quantum dot-antibody conjugate agglomerates; detecting the presence of the biomarkers by excitation of the agglomerates.

Claims

1. A method of detecting a biomarker, comprising:

coupling quantum dots to a molecular recognition element that binds to a biomarker of interest to form functionalized conjugates;

providing a sample from a subject;

introducing the sample and the functionalized conjugates to at least one sample holding channel in an incubation chamber to form agglomerates through self-assembly if contacted with the corresponding biomarker;

detecting the agglomerate by at least one of the rate of agglomeration and/or the number of agglomerates.

2. The method of claim 1, wherein the detecting step includes correlating antigen concentration with agglomerate formation.

3. The method of claim 1, wherein the molecular recognition element is an antibody.

4. The method of claim 1, wherein the rate of agglomeration correlates with a disease state.

5. The method of claim 4, wherein the disease state is cancer.

6. The method of claim 1, comprising coupling a second set of quantum dots to a second molecular recognition element that binds to a second biomarker of interest to form a second set of functionalized conjugates;

introducing the sample and the second set of functionalized conjugates to at least one sample holding channel in an incubation chamber to form a second set of agglomerates through self-assembly if contacted with the corresponding biomarker; and

detecting the second set of agglomerates by at least one of the rate of agglomeration and/or the number of agglomerates.

7. The method of claim 1, wherein the biomarker is indicative of a cancer.

8. The method of claim 1, wherein the biomarker is indicative of cancer metastasis.

9. The method of claim 7, wherein the cancer is one that metastasizes in bone.

10. The method of claim 9, wherein the cancer is lung, breast, or prostate cancer.

11. The method of claim 1, wherein the biomarkers include at least one of a protein, protein fragment, DNA, RNA, or oligosaccharide.

12. The method of claim 1, wherein the biomarker is at least one of TGF-β

1, osteoprotegerin, parathyroid hormone protein, and bone specific alkaline phosphatase.

13. The method of claim 1, wherein the biomarker is at least one of c-ErB-2, sEGFR, or galectin-3.

14. The method of claim 1, wherein self-assembly results in at least a 1000-fold or greater change in volume when compared to a single quantum dot.